RT Journal Article
SR Electronic
A1 Poljaková, Jitka
A1 Forsterová, Kristina
A1 Šulc, Miroslav
A1 Frei, Eva
A1 Stiborová, Marie
T1 OXIDATION OF AN ANTITUMOR DRUG ELLIPTICINE BY PEROXIDASES
JF Biomedical papers
YR 2005
VO 149
IS 2
SP 449
OP 453
DO 10.5507/bp.2005.078
UL https://biomed.papers.upol.cz/artkey/bio-200502-0054.php
AB Ellipticine is a potent antineoplastic agent, whose mode of action is considered to be based mainly on DNA intercalation and/or inhibition of topoisomerase II. Since we found that ellipticine also forms the cytochrome P450 (CYP)-mediated covalent DNA adducts, this anticancer drug is considered to function as a pro-drug, whose pharmacological efficiency and/or genotoxic side effects are dependent on its enzymatic activation in target tissues. Here, we demonstrate that ellipticine is also oxidized by peroxidases, which are abundantly expressed in several target tumor tissues. Lactoperoxidase, myeloperoxidase and horseradish peroxidase were used as models. Peroxidases in the presence of hydrogen peroxide oxidize ellipticine to an ellipticine dimer and N<sup>2</sup>-oxide of ellipticine as the major and minor metabolite, respectively. Inhibition of the peroxidase-mediated ellipticine oxidation by radical scavengers ascorbate, glutathione and NADH suggests a one-electron mechanism of the oxidation. The implication of the oxidation of ellipticine by peroxidases in its mechanism of action is discussed.